Novo Nordisk A/s

Novo Nordisk Healthcare Ag

Jais Rose Bjelke

Thomas Egebjerg

Philip Jonas Sassene

Marie-Ange Buyse

Jens Breinholt

Lars Christian Petersen

Soren Steffensen

Frantisek Hubalek

Ida Hilden

Steffen Reedtz-Runge

Jes Thorn Clausen

Susanne Nedergaard Grell

Mathias Norrman

Mette Dahl Andersen

Andreas Vegge

Evelyn De Tavernier

Per J Greisen

Jacob Lund

Daniele Granata

Simone Fulle

Emma Balantic-Nielsen

Che Yang

Katharina Luise Maria Kopp

The present invention relates to compounds (e.g. ISVDs, polypeptides, polypeptide derivatives) capable of binding to Interleukin-6 (IL-6) and their use in the treatment of inflammatory diseases such as, e.g. cardiovascular disease (CVD).

Anti IL-6 domain antibodies with fatty acid substituents

The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.

Highly potent ISVD compounds capable of substituting for FVIII(A)

The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention.

Targeting tissue factor to activated platelets

The present invention relates to the purification of vitamin K-dependent blood coagulation factors, such as Factor IX (FIX). In particular, the invention provides a method for purifying Factor IX having a desired content of gamma-carboxyglutamic acid from a sample comprising a mixture of species of said Factor IX having different contents of gamma-carboxyglutamic acid, said method comprising the steps of: (a) loading said Factor IX sample onto an immunoaffinity chromatography material coupled to a binding moiety for gamma-carboxyglutamic acid; (b) eluting said Factor IX; and (c) selecting a fraction obtained from said elution wherein the polypeptides in the fraction have the desired content of gamma-carboxyglutamic acids; characterized in that the total concentration of Factor IX within said sample exceeds the binding ability of the immunoaffinity chromatography material.

Purification of blood coagulation factors

Growing community of inventors

Smoerum, Denmark

Jais Rose Bjelke